Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255967 | 0.70 | KEAP1 (0.48) | KEAP1GPR3PLCG1MAOAABCG2 | |
| SCHEMBL29398545 | 0.70 | KEAP1 (0.48) | KEAP1GPR3PLCG1MAOAABCG2 | |
| SCHEMBL8011773 | 0.69 | KEAP1 (0.42) | KEAP1GPR3MAOA | |
| Hydrochloric Acid SCHEMBL29656759 | 0.68 | KEAP1 (0.47) | KEAP1GPR3PLCG1MAOAABCG2 | |
| SCHEMBL255969 | 0.67 | KEAP1 (0.55) | KEAP1ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL19695681 | 0.65 | KEAP1 (0.36) | KEAP1GPR3MAOA | |
| SCHEMBL19821085 | 0.64 | MAOA (0.48) | MAOA | |
| SCHEMBL29465618 | 0.62 | CA12 (0.41) | KEAP1GPR3MAOA | |
| SCHEMBL19406510 | 0.62 | CA12 (0.41) | KEAP1GPR3MAOA | |
| SCHEMBL255966 | 0.61 | GPR3 (0.46) | KEAP1GPR3PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | LCK, TYRO3, ABL1 | KEAP1 3153/4885GPR3 2484/4885PLCG1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.